- ORSL entered into a strategic business development & service collaboration with General Carbon Advisory Services for sustainability and carbon management.
- Focus is on Carbon Border Adjustment Mechanism (CBAM) advisory and compliance support — a high-value, rapidly growing area given evolving EU import regulations.
- ORSL will leverage its industrial relationships and market presence to identify organizations requiring CBAM preparedness, carbon reporting, and emissions data management.
- General Carbon Advisory Services will provide specialized technical advisory, assessments, reporting frameworks, and verification support.
- This marks ORSL's strategic expansion beyond waste valorisation, bioenergy, and environmental engineering into sustainability advisory services.
- Intraday volume was thin at only 600 shares; BSE Group 'M' stock indicating small-cap, low-liquidity nature.
- Secured a civil infrastructure order worth Rs 373 crore in April 2026 under its Urban Infrastructure and Metro Business Unit.
- Order involves Engineering, Procurement and Construction (EPC) contracts with tunneling using TBM (Tunnel Boring Machine) technology.
- Institutional holding is strong at 33.14%, reflecting significant institutional investor confidence in the company.
- Stock is trading well below its 52-week high of Rs 479.05, suggesting potential recovery headroom if order momentum continues.
- Intraday range was wide (Rs 339.65–Rs 356.05) indicating active price discovery on the news.
- Awarded a landmark order worth Rs 750.82 crore (incl. GST) from the Reserve Bank of India (RBI) — the largest single order for this company.
- Order is for Supply, Installation, Implementation, Integration, Maintenance & Facilities Management Services for Private Cloud Infrastructure for RBI Data Centers.
- RBI is establishing a new Greenfield Next Generation Data Centre (NGDC) at Bhubaneswar, Odisha — a state-of-the-art, energy-efficient facility.
- Scope includes Servers, Unified Native Storage, SAN Switches, Physical Racks, associated Software Licenses, and 5-year support.
- Solution is designed to enable secure integration with RBI's AI Cloud infrastructure — forward-looking design for AI workloads.
- Dynacons responsible for end-to-end supply, design, installation, integration with existing data center ecosystem, and ongoing technical support.
- Stock hit a fresh 52-week high today on the order announcement, confirming significant market re-rating of the company.
- Subsidiary Nibe Space received Letter of Award (LoA) worth Rs 12.58 crore (incl. all taxes) from Maharashtra State Electricity Distribution Co. Ltd. (MSEDCL).
- Project is titled GIS Survey, Mapping & Data Preparation of MSEDCL's Distribution Network — involves comprehensive digitization.
- Covers the network from 33 KV substations to end consumer service points, including both overhead and underground infrastructure.
- Order execution timeline is 42 months in tranches — long-dated revenue visibility for the subsidiary.
- Stock is trading significantly below 52-week high of Rs 2,000.55, indicating the stock has corrected sharply from peak; this win may support sentiment.
- Wholly owned subsidiary Meghmani Crop Nutrition (MCNL) received approval from the Ministry of Agriculture and Farmers Welfare for manufacturing nano fertilizer products.
- Products approved: Nano DAP, Nano NPK, and Nano Zinc — three distinct nano fertilizer categories targeting different crop nutrition needs.
- Manufacturing will be at the company's existing Sanand facility, Gujarat — no additional capital expenditure required, enhancing return on existing assets.
- Commercial production expected to commence during Kharif season (typically June–July 2026).
- These products support India's push for next-generation precision agriculture and are expected to strengthen the company's crop nutrition portfolio significantly.
- Stock surged ~10.6% intraday, touching a high of Rs 58.49, reflecting strong market enthusiasm for this diversification into high-growth agri-tech.
- Completed the acquisition of Optimum Healthcare IT, a Best in KLAS healthcare digital transformation and consulting firm.
- Optimum specializes in helping provider organizations drive large-scale transformation across clinical and operational environments.
- This significantly enhances Infosys' presence in the healthcare provider segment, adding new clients, relationships, and expanded technology capabilities.
- Combination of Optimum's provider expertise with Infosys Topaz and Infosys Cobalt is expected to create a differentiated value proposition for healthcare providers.
- Together, the companies aim to deliver AI-powered, large-scale cloud and data transformation for healthcare providers, improving patient experiences and operational efficiency.
- Stock is trading near its 52-week low zone (low: Rs 1,149.80 on Apr 28), suggesting the market is in a cautious phase despite the strategic acquisition news.
- Standalone Q4FY26: Net profit rose 18.88% YoY to Rs 777.04 Cr; total income up 18.17% to Rs 4,583.78 Cr.
- Consolidated Q4FY26: Net profit surged 30.60% YoY to Rs 1,129.16 Cr; total income up 10.11% to Rs 13,475.74 Cr.
- Full Year FY26 (Consolidated): Net profit rose 5.14% YoY to Rs 3,109.32 Cr; total income up 13.06% to Rs 17,585.04 Cr.
- Consolidated profit growth (30.6%) significantly outpaced standalone growth (18.9%), suggesting subsidiaries performed exceptionally well in Q4.
- Promoter holding is high at 68.51% (Aditya Birla Group), providing governance stability; institutional holding at 20.83%.
- Stock is trading close to its 52-week high of Rs 369.25 — strong results may push it to test new highs.
- Received Letter of Award (LoA) from UP Jal Nigam (Urban), Varanasi for laying sewer network and house connection work.
- Work covers 5 of 18 problematic wards in Varanasi: Durgakund, Nariyan, Sarainandan, Jolha Northan, and Bhelupur.
- Estimated order value (excluding GST) is Rs 143.79 crore, with execution timeline of 24 months.
- This is a government (urban local body) order, providing relatively stable revenue certainty.
- Stock touched a high of Rs 372.15 intraday — significant recovery from 52-week low of Rs 256.50 but still well below 52-week high of Rs 681.45.
- Standalone Q4FY26: Net profit up 22.72% YoY to Rs 312.44 Cr; total income up 9.34% to Rs 4,565.30 Cr.
- Consolidated Q4FY26: Net profit up 15.19% YoY to Rs 215.25 Cr; total income up 8.23% to Rs 4,739.37 Cr.
- Full Year FY26: Net profit up 3.19% YoY to Rs 1,111.33 Cr; total income up 4.06% to Rs 17,361.99 Cr.
- Standalone profit growth (22.7%) outpaced consolidated (15.2%), indicating that standalone operations performed better than subsidiaries in Q4.
- Full-year net profit growth was modest at 3.19%, suggesting a challenging operating environment despite Q4 improvement.
- Institutional holding is significant at 29.42%, indicating considerable institutional interest in this large-cap battery manufacturer.
- Standalone Q4FY26: Net profit up 10.64% YoY to Rs 159.13 Cr; total income up 6.41% to Rs 863.30 Cr.
- Consolidated Q4FY26: Net profit up 8.10% YoY to Rs 204.17 Cr; total income surged 19.40% YoY to Rs 1,603.18 Cr — a strong revenue quarter.
- Full Year FY26 (Consolidated): Net profit fell 32.82% YoY to Rs 570.41 Cr; total income declined 2.05% to Rs 3,438.21 Cr — a difficult year overall.
- The sharp fall in full-year profit despite a good Q4 suggests the company faced significant headwinds in H1 FY26, with Q4 showing recovery.
- Volume was extremely high at 17.73 lakh shares traded intraday — indicating strong market interest and position readjustment on results.
- Stock remains ~20% below 52-week high of Rs 797; the Q4 recovery results may serve as a positive catalyst for further recovery.
- Highest-ever quarterly revenue in Q4 FY26; Non-MF business grew 24.5% YoY; Enterprise revenue up 11% YoY.
- Absolute EBITDA reached an all-time high of Rs 183.66 Cr, with EBITDA margin at a healthy 46.5%.
- CAMS AuM at Rs 55.1 lakh Cr, retaining ~68% market share, up 21% YoY. Equity assets hit all-time high of Rs 30.5 lakh Cr (67% share).
- New SIP registrations reached 1.26 Cr in Q4FY26 — 46% YoY growth, outpacing industry growth of 37%. Annual SIP registrations in FY26: 4.7 Cr.
- SIP collections crossed Rs 20,000 Cr milestone in March; total Q4 SIP collections at Rs 58,889 Cr (+24% YoY).
- Live SIPs grew 17% YoY vs. industry 4%; CAMS' SIP market share rose to 64.1% from 57.0% last year.
- Unique investor base crossed 4.76 Cr — 18% YoY growth vs. industry 13%.
- Added Oaklane Capital LLP and Neo Investments Value Advisors as MF RTA clients; total MF RTA clients now at 31.
- Transaction volumes for FY26: 107 Cr (+20% YoY). Four SIFs launched maiden funds; 8 more launches expected.
- Non-MF revenue contribution: 15.3% of enterprise revenue. CAMSPay +22.8% YoY; CAMS Alternatives +25.4% YoY (AUM: Rs 3.1 lakh Cr, 50%+ outsourced market share).
- CAMS KRA: +28% YoY revenue despite industry headwinds. CAMSRep: +6% YoY; Bima Central doubled active user base adding 12.6 lakh users in FY26.
- Multi-year platform re-architecture delivering outcomes — revenue growth achieved on near flat headcount, reflecting automation gains.
- GIFT City Retail Fund AuM: US $35.3 Mn; ConsenPro (DPDPA consent management platform) gaining early BFSI enterprise engagement.
- Received order worth Rs 4.31 crore from Souraj Energy for development of a grid-connected solar ground-mounted captive power plant — 1,250 kW (DC) / 900 kW (AC).
- Order to be executed within approximately 6 months on a turnkey EPC basis.
- Earlier also received aggregate domestic EPC orders worth Rs 19.27 crore (inclusive of applicable taxes) in the ordinary course of business.
- Stock hit a fresh 52-week high of Rs 125.00 today — strong bullish momentum driven by order wins in the solar EPC space.
- BSE Group 'M' stock — micro-cap, high promoter holding (70%); limited institutional participation (9.08%).
- Acquired approximately 15 acres of prime waterfront land (with an additional 5-acre expansion option) at Saphale, Palghar, Maharashtra via subsidiary Knowledge Shipyard.
- Site is located along the Vaitarna River, close to the upcoming Vadhvan Port — offering strong multimodal connectivity and natural marine advantages.
- Features include ~188m waterfront access, a natural slipway with ~6m high-tide draft, and robust river width enabling efficient vessel movement.
- Marks KMEW's strategic pivot into technology-driven, sustainable commercial shipbuilding — a significant business expansion beyond existing operations.
- Stock touched a fresh 52-week high of Rs 2,220.50 today; the stock has tripled from its 52-week low of Rs 655.00 — reflecting dramatic re-rating.
- Institutional holding at 13.47% — growing institutional interest in this emerging maritime infrastructure play.
- Received a work order worth Rs 83 lakh from Hindustan Aeronautics Limited (HAL) for the supply of New Product — Active Network Components.
- Order to be executed within 90 days — short-cycle, high-urgency defence supply contract.
- HAL is a government-owned aerospace and defence manufacturer — providing credibility and potential for repeat orders.
- Micro-cap stock (Mkt Cap Rs 37.91 Cr) with very high promoter holding of 73.52%; very thin traded volumes (only 6,000 shares today).
- Stock is trading at less than half its 52-week high of Rs 58.00, suggesting significant downside from peak valuations.
- Expanded manufacturing footprint with a new, large-scale facility in Kundli, Haryana, focused on the fast-growing athleisure and sports footwear segment.
- Signed a rent agreement; production capacity expected to scale from ~1 lakh pairs/month to 5 lakh pairs/month in a phased manner — a 5x expansion.
- Commercial operations expected from Q2 FY26 onwards (note: this likely means Q2 FY27 given announcement timing in May 2026).
- New Kundli unit will be equipped with advanced manufacturing technologies for sports shoes and EVA-based footwear.
- Facility will support the company's in-house athleisure brand 'Rannr' and its OEM manufacturing vertical.
- BSE Group 'X' stock — Smallest segment; minimal institutional presence (0.26%); high promoter control (72.90%).
- Received repeat international purchase orders from existing overseas customer Taha Drugs & Chemicals Co for supply of nutraceutical products.
- Order value: USD 84,450 (approximately Rs 70–71 lakh at current exchange rates) — modest in size but significant as a repeat order confirming customer satisfaction.
- Orders to be executed within mutually agreed timelines as per purchase order and shipment schedule.
- Repeat orders signal strengthening international business relationships and growing global presence.
- Micro-cap company with mkt cap of Rs 51.18 Cr; promoter holding is relatively low at 44.99%; 55.01% held by non-institutions.
- Q4FY26: Net profit up 25.50% YoY to Rs 284.31 Cr; total income up 19.22% to Rs 3,519.25 Cr — a strong double-digit growth quarter.
- Both revenue and profit growth are among the stronger prints reported today, reflecting robust demand in the cables & wires sector.
- Institutional holding is very high at 53.10% with promoter at only 35.00% — one of the more institutionally-held stocks in today's list.
- Stock is trading near its 52-week high zone (high: Rs 5,301.10), suggesting the market has largely priced in the strong performance.
- Intraday range was wide (Rs 4,722.30 – Rs 5,131.80), indicating active price discovery and profit-booking at higher levels.
- Wholly owned subsidiary Premier Energies Global Environment received approval and entered into a Share Subscription and Shareholders' Agreement (SSSHA).
- To acquire a minimum 26% equity stake (aggregating Rs 68.70 Cr) in Hexa Energy BH Five (SPV) — a renewable energy generation and transmission company.
- Investment is intended to meet captive power consumption requirements for its Solar PV Cell Manufacturing Project at Naidupeta, Andhra Pradesh.
- Transaction expected to complete in approximately 16 months from agreement execution, subject to conditions precedent.
- Board of directors of Premier Energies Global Environment approved the same on May 4, 2026.
- This is a strategic backward integration — securing renewable energy supply for manufacturing operations, improving cost structure and sustainability profile.
- Received WHO Prequalification approval for anti-malarial API Amodiaquine Hydrochloride USP — an essential medicine widely used in combination therapies for uncomplicated Plasmodium falciparum malaria.
- WHO Prequalification evaluates quality, safety, and efficacy to international standards, aiding UN agencies and countries in procuring reliable health products.
- This strengthens Anuh Pharma's position as a preferred API supplier for global anti-malarial programs.
- Recently completed a successful USFDA inspection; also holds a Certificate of Suitability from the European drug regulator for Sulfadimethoxine (Antibiotic API).
- Strong global footprint: 360 customers across 59+ countries including Europe, Mexico, and South Africa.
- Manufacturing facility at Tarapur, Maharashtra; one of India's largest manufacturers of Macrolides and Anti-TB products; employs 2,000+ people.
- ~55% of FY25 revenue from exports — making WHO/regulatory approvals critical to its business model and market access.
- HFCL along with HTL (a material subsidiary) secured purchase orders worth approximately Rs 84.23 crore for supply of optical fiber cables (OFC) from a leading private telecom operator.
- Orders to be executed by August 2026 — short-cycle, near-term revenue visibility.
- Non-institutional holding is very high at 57.61% — dominated by retail and non-institutional investors.
- Stock breached its prior 52-week high of Rs 128.40 (set just yesterday, May 4) today, touching Rs 133.40 intraday — a fresh multi-week high momentum.
- Volume was exceptionally high at 46 lakh+ shares traded — significant market activity suggesting active institutional and retail participation.
- Subsidiary Caplin Steriles (CSL) received final USFDA approval for its ANDA for Calcium Gluconate Injection USP (100 mg/mL in 10 mL, 50 mL, and 100 mL vials).
- Generic equivalent of the Reference Listed Drug (RLD) from Fresenius Kabi USA, LLC.
- Calcium Gluconate Injection is indicated for pediatric and adult patients for treatment of acute symptomatic hypocalcemia.
- US market size: Approximately USD 71 million for the 12-month period ending March 2026 (per IQVIA/IMS Health) — a meaningful market opportunity.
- High promoter holding of 70.57% provides governance stability; institutional holding at 8.29%.
- Stock is significantly below 52-week high of Rs 2,396.95; USFDA approval may serve as a positive catalyst for the stock going forward.
- Domestic Institutional Investors (DIIs) hit a record 20.9% holding in Nifty 500 in March 2026 — the eighth consecutive quarter of increase, up 170 bps YoY and 50 bps QoQ.
- Foreign Institutional Investors (FIIs) slipped to a fresh low of 17.1%, down 180 bps YoY — the FII-DII ratio is now 0.8x, marking a decisive structural shift.
- In Q1 CY2026, DIIs pumped USD 27.2 billion into Indian equities; FIIs pulled out USD 15.8 billion, with USD 14.2 billion exiting in March alone — triggered by the escalating Iran conflict.
- The primary driver behind DII strength: steady inflows through Systematic Investment Plans (SIPs).
- MOFSL noted: once geopolitical uncertainty settles, there is a high likelihood of improved FII flows returning to Indian markets.
- DIIs raised stakes in 21 of 24 sectors YoY — sharpest increases in private banks, technology, telecom, real estate, and healthcare.
- FIIs cut holdings in 17 sectors; their technology sector allocation fell to an all-time low of 7.3%.
- Promoter holdings edged up 40 bps QoQ to 49.4%; retail holdings rose modestly to 12.7%.
- DIIs raised stakes across large-cap, mid-cap, and small-cap — all DII segments touching record highs simultaneously.
- Nifty 500 has gained approximately 80% in the last 5 years; since the US-Iran war began (Feb 28), the index is down just 0.02% (5 points from 22,835.95 to 22,830.75) — showing remarkable resilience.
SEBI Disclaimer — Important Notice to Investors
SEBI Registration: Investment in securities market is subject to market risks. Read all scheme related documents carefully before investing.
Not Investment Advice: This report is compiled solely for informational and educational purposes. Nothing contained herein constitutes or should be construed as investment advice, a solicitation, an offer to buy or sell any securities, or a recommendation to invest in any financial instrument.
Source Disclaimer: The information compiled in this report is based on company announcements, BSE/NSE exchange filings, and publicly available disclosures. While care has been taken to reproduce figures accurately, readers are advised to independently verify all data on official BSE (www.bseindia.com) and NSE (www.nseindia.com) portals before making any investment decision.
No Guarantee of Accuracy: Past performance of any stock or financial instrument is not indicative of future results. Price data, order values, and shareholding information are as reported on May 5, 2026 and are subject to change. The publisher does not guarantee the accuracy, completeness, or timeliness of any information contained herein.
Risk Disclosure: Equity investments are subject to market risks, including but not limited to price risk, liquidity risk, sector risk, regulatory risk, and geopolitical risk. Investors can lose part or all of their invested capital. Micro-cap and small-cap stocks carry higher liquidity risk and volatility.
SEBI Investor Grievance Redressal: For any grievances, investors may contact SEBI at www.scores.sebi.gov.in | Toll Free: 1800 266 7575 | Email: sebi@sebi.gov.in
SEBI Registered Investment Advisors (RIA): Investors are encouraged to take guidance only from SEBI-registered Investment Advisors before making any investment decision. Unregistered advice may be misleading and illegal.
Disclaimer: The views expressed in this report are of the author/compiler only and do not represent the views of any exchange, regulator, or financial institution. This content is NOT a research report as defined under SEBI (Research Analysts) Regulations, 2014. Readers are advised to exercise independent judgment and consult their SEBI-registered financial advisor before acting on any information.